Corcept Therapeutics Inc (NASDAQ: CORT) has a price-to-earnings ratio that is above its average at 43.57x. The stock has a 36-month beta value of 0.50. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for CORT is 90.20M, and at present, short sellers hold a 20.84% of that float. On November 15, 2024, the average trading volume of CORT was 918.17K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CORT) stock’s latest price update
The stock price of Corcept Therapeutics Inc (NASDAQ: CORT) has plunged by -2.94 when compared to previous closing price of 56.45, but the company has seen a 0.90% gain in its stock price over the last five trading sessions. zacks.com reported 2024-11-11 that Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
CORT’s Market Performance
CORT’s stock has risen by 0.90% in the past week, with a monthly rise of 15.91% and a quarterly rise of 61.29%. The volatility ratio for the week is 6.57% while the volatility levels for the last 30 days are 5.36% for Corcept Therapeutics Inc The simple moving average for the last 20 days is 6.51% for CORT stock, with a simple moving average of 66.91% for the last 200 days.
Analysts’ Opinion of CORT
Many brokerage firms have already submitted their reports for CORT stocks, with Truist repeating the rating for CORT by listing it as a “Buy.” The predicted price for CORT in the upcoming period, according to Truist is $38 based on the research report published on November 06, 2023 of the previous year 2023.
SVB Securities, on the other hand, stated in their research note that they expect to see CORT reach a price target of $25. The rating they have provided for CORT stocks is “Market Perform” according to the report published on April 11th, 2023.
Piper Sandler gave a rating of “Overweight” to CORT, setting the target price at $27 in the report published on April 04th of the previous year.
CORT Trading at 18.82% from the 50-Day Moving Average
After a stumble in the market that brought CORT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.15% of loss for the given period.
Volatility was left at 5.36%, however, over the last 30 days, the volatility rate increased by 6.57%, as shares surge +16.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +60.67% upper at present.
During the last 5 trading sessions, CORT rose by +0.90%, which changed the moving average for the period of 200-days by +159.67% in comparison to the 20-day moving average, which settled at $51.44. In addition, Corcept Therapeutics Inc saw 68.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CORT starting from Swisher Daniel N JR, who sale 2,200 shares at the price of $59.88 back on Nov 11 ’24. After this action, Swisher Daniel N JR now owns 0 shares of Corcept Therapeutics Inc, valued at $131,736 using the latest closing price.
Swisher Daniel N JR, the Director of Corcept Therapeutics Inc, proposed sale 2,200 shares at $59.88 during a trade that took place back on Nov 11 ’24, which means that Swisher Daniel N JR is holding shares at $131,736 based on the most recent closing price.
Stock Fundamentals for CORT
Current profitability levels for the company are sitting at:
- 0.23 for the present operating margin
- 0.98 for the gross margin
The net margin for Corcept Therapeutics Inc stands at 0.23. The total capital return value is set at 0.22. Equity return is now at value 25.53, with 20.38 for asset returns.
Based on Corcept Therapeutics Inc (CORT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 334.85. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 40.03.
Currently, EBITDA for the company is 108.32 million with net debt to EBITDA at -0.9. When we switch over and look at the enterprise to sales, we see a ratio of 8.93. The receivables turnover for the company is 10.53for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.70.
Conclusion
To sum up, Corcept Therapeutics Inc (CORT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
